SEC Company Response from Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248) (CMMB) — May 12, 2021
Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248)
Date: May 12, 2021 · CIK: 0001534248 · Accession: 0001104659-21-065032
AI Filing Summary & Sentiment
File numbers found in text: 333-255658
Letter
May 12, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Jane Park
Re: Chemomab Therapeutics Ltd.
Registration Statement on Form S-3
Filed April 30, 2021
File No. 333-255658
Acceleration Request
Requested Date: May 17, 2021
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-255658) (the “Registration Statement”), to become effective on May 17, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so confirm that event with our outside counsel, Mr. David S. Glatt of Meitar | Law Offices, by email at dglatt@meitar.com. The Company hereby authorizes Mr. Glatt to orally modify or withdraw this request for acceleration.
[Signature page follows]
Very truly yours,
Chemomab Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
May 12, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn:
Jane Park
Re:
Chemomab Therapeutics Ltd.
Registration Statement on Form S-3
Filed April 30, 2021
File No. 333-255658
Acceleration Request
Requested Date: May 17, 2021
Requested Time: 4:00 p.m. Eastern
Time
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests
that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced
Registration Statement on Form S-3 (File No. 333-255658) (the “Registration Statement”), to become effective
on May 17, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally
request via telephone call to the Commission’s staff.
It would be appreciated if,
promptly after the Registration Statement has become effective, you would so confirm that event with our outside counsel, Mr. David S.
Glatt of Meitar | Law Offices, by email at dglatt@meitar.com. The Company hereby authorizes Mr. Glatt to orally modify or
withdraw this request for acceleration.
[Signature page follows]
Very truly yours,
Chemomab Therapeutics Ltd.
By:
/s/ Sigal Fattal
Sigal Fattal
Chief Financial Officer
cc:
Sigal Fattal, Chemomab Therapeutics Ltd.
David S. Glatt, Adv., Meitar | Law Offices